IBRX
ImmunityBio, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
ImmunityBio (IBRX) Stock: Buy, Sell, or Hold?
$6.10
-0.57 (-8.55%)
▼
5d:
-23.85%
30d:
-38.45%
90d:
-19.42%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 10, 2026
0d
Protect IBRX Gains
Updated Nov 12, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (57%)
Quality Score
40/100
Position
OVERSOLD
30-Day Fair Range
$7.59 – $9.81
Position: OVERSOLD
Forward P/E & Valuation
-91.0x
CHEAP
vs 132.4x historical avg
Wall Street Target
$14.25
+113.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$6.10 / $8.95
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: IBRX is down 23.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Nov 9, 2026 at $7.29 · last confirmed Nov 11, 2026
Strength: 8.1/10
Get Alerted When IBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: IBRX is currently trading at $6.10, which is considered oversold relative to its 30-day fair value range of $7.59 to $9.81. From a valuation perspective, the stock is trading at a discount (Forward PE: -91.0) compared to its historical average (132.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IBRX is in a downtrend. The price is currently testing key support at $6.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.5% recently.
Market Sentiment: IBRX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.25 (+113.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IBRX is in a downtrend. The price is currently testing key support at $6.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.5% recently.
Market Sentiment: IBRX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.25 (+113.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.59 -
$9.81
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
Trading Range & Key Levels
30-Day Trading Range
$7.59 -
$9.81
Current vs Trading Range
OVERSOLD
Support Level
$6.10
Resistance Level
$8.95
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Protect Your Profits
Holding IBRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.5%)
- BULLISH: Trading 113.6% below Wall St target ($14.25)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-91.00
Wall Street Target
$14.25
(+113.6%)
Revenue Growth (YoY)
52.3%
PE vs Historical
-91.0 vs 132.4
CHEAP
Share IBRX Analysis
Share this live IBRX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (IBRX)
Bearish
5 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
4 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
IBRX stock experienced its worst week in nearly 2 years, but bullish sentiment on StockTwits remains strong due to the potential of Anktiva's label expansion for sepsis treatment in the US and Europe.
Key Retail Themes:
Sepsis trials
Label expansion
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 41 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Advanced IBRX Option Strategies
Professional options setups generated by AI based on today's IBRX price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive IBRX Research Pages
